📰 Nasdaq Elev News
Page 2 - Nasdaq Elev News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Nasdaq Elev. Real-time updates on events, politics, business and more.
June 2, 2023
SVB Securities upgraded shares of Elevation Oncology (NASDAQ:ELEV – Get Rating) from a market perform rating to an outperform rating in a report released on Tuesday morning, The Fly reports. They currently have $8.00 price objective on the stock, up from their previous price objective of $5.00. Separately, Wedbush reaffirmed an outperform rating and issued […]
May 25, 2023
Elevation Oncology, Inc. (NASDAQ:ELEV – Get Rating) saw a significant decline in short interest in the month of May. As of May 15th, there was short interest totalling 369,100 shares, a decline of 64.2% from the April 30th total of 1,030,000 shares. Based on an average daily trading volume, of 822,600 shares, the days-to-cover ratio […]
May 24, 2023
Elevation Oncology (NASDAQ:ELEV – Get Rating) and Freeline Therapeutics (NASDAQ:FRLN – Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk. Institutional & Insider Ownership 68.0% of Elevation Oncology shares […]
May 18, 2023
Elevation Oncology, Inc. (NASDAQ:ELEV – Get Rating) – Investment analysts at Wedbush lifted their Q2 2023 earnings per share estimates for Elevation Oncology in a research note issued on Monday, May 15th. Wedbush analyst R. Driscoll now expects that the company will earn ($0.25) per share for the quarter, up from their prior estimate of […]
May 11, 2023
Elevation Oncology, Inc. (NASDAQ:ELEV – Get Rating) was the recipient of a large growth in short interest in the month of April. As of April 30th, there was short interest totalling 1,030,000 shares, a growth of 688.7% from the April 15th total of 130,600 shares. Based on an average daily trading volume, of 766,300 shares, […]
May 10, 2023
Elevation Oncology, Inc. (NASDAQ:ELEV – Get Rating) saw a significant growth in short interest in April. As of April 30th, there was short interest totalling 1,030,000 shares, a growth of 688.7% from the April 15th total of 130,600 shares. Based on an average daily volume of 766,300 shares, the short-interest ratio is presently 1.3 days. […]
April 15, 2023
Elevation Oncology, Inc. (NASDAQ:ELEV – Get Rating) saw a significant increase in short interest in the month of March. As of March 31st, there was short interest totalling 123,200 shares, an increase of 135.6% from the March 15th total of 52,300 shares. Approximately 0.8% of the shares of the company are sold short. Based on […]
May 9, 2022
Elevation Oncology (NASDAQ:ELEV – Get Rating) is one of 255 public companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its rivals? We will compare Elevation Oncology to similar companies based on the strength of its profitability, valuation, risk, earnings, dividends, institutional ownership and analyst recommendations. Insider & […]
April 9, 2022
Elevation Oncology, Inc. (NASDAQ:ELEV – Get Rating) has earned a consensus rating of “Buy” from the six analysts that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12 month target price among […]